<DOC>
	<DOCNO>NCT02189772</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability single administration Metadoxine Extended Release ( MDX ) formulation treatment adolescent diagnose ADHD predominantly inattentive symptom . The study also try evaluate efficacy MDX level blood .</brief_summary>
	<brief_title>Safety Tolerability Study Metadoxine Extended Release ( MDX ) ( Previously Known MG01CI ) PI-ADHD Adolescent Subjects</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled multi-center , fix dose , single dose study adolescent subject PI-ADHD . Eligible subject randomize 1:1 ratio receive single administration either MDX ( approximately 14-22 mg/kg ) match placebo . Subjects take course methylphenidate , amphetamine atomoxetine least two week prior screen require 2-week wash-out ( methylphenidate , amphetamine ) 4-week wash-out ( atomoxetine ) request attend interim screen visit . The study consist three period : screening period three week ( five case atomoxetine washout ) , 1 day treatment period , one-week safety follow-up period . Overview Study Visits Screening Period - Visit 1 ( Screening/Baseline ) Following signing informed consent/assent , subject screen study eligibility . Each subject undergo battery evaluation various rating scale include Adolescent ADHD Clinical Diagnostic Scale1 ( ACDS v1.2 ) , Kiddie - Schedule Affective Disorders Schizophrenia - Present Lifetime Version ( K-SADS-PL ) , Columbia-Suicide Severity rating scale ( C-SSRS ) , State Trait Anxiety Inventory ( STAI-A STAI-T ) , Beck Depression Inventory ( BDI ) , CGI-S ( Clinical Global Impression - Severity ) , Time-Sensitive ADHD Symptom Scale ( TASS ) , Wechsler Intelligence Scale Children- fourth edition ( WISC-IV ) sub-tests2 Test Variables Attention ( TOVA ) 3 . Eligible subject require wash-out , eligible study . In addition , follow standard assessment perform : assessment inclusion/exclusion , collection demographic data , medical history , prior medication , neurological exam , neuropathy questionnaire , physical exam , height weight , vital sign , ECG , laboratory evaluation include hematology ( complete blood count , CBC ) , chemistry , plasma concentration metadoxine , urinalysis , serum pregnancy test woman child bear potential . The screen visit may conduct multiple day . Screening visit data consider baseline data statistical analysis purpose subject require washout . Visit 1a ( Interim screen visit ) This visit applicable subject take medication supplement require washout methylphenidate , amphetamine atomoxetine time 2 week precede Visit 1 ( screen ) ; subject undergo 2-week washout ( case methylphenidate amphetamine treatment ) 4-week washout ( case atomoxetine treatment ) period attend interim screen visit . Baseline TOVA , WISC-IV sub-tests1 , TASS perform Visit 1a . In addition , C-SSRS , adverse event , concomitant medication record visit . Treatment Period - Visit 2 ( Day 1 , visit window + 3 day ) At study visit 2 ( Day 1 ) , eligible subject randomize 1:1 allocation receive either MG01CI match placebo ; dose determine weight screen visit 1 . Investigational product administer clinic . The WISC-IV sub-test Digit Span , Coding , Letter Number Sequencing , Symbol Search administer . Subjects undergo evaluation TOVA test 3 5 hour post-dose assess response treatment . In addition , subject complete TASS prior administration study drug , 3-5 hour post-dose . At visit , subject also undergo safety assessment include urine pregnancy test ( pre-dose ) , vital sign , neurological exam , neuropathy questionnaire , C-SSRS record adverse event ( AEs ) concomitant medication . Subjects blood drawn plasma concentration metadoxine 1-2 hour post-dose 3-4 hour post-dose . Follow-Up Period - Visit 3 ( Day 8 , visit window ± 3 day ) One week end treatment , subject complete TASS undergo safety assessment include physical exam , neurological exam , neuropathy questionnaire , vital sign , ECG , laboratory evaluation ( hematology , chemistry , urinalysis include urine pregnancy test woman child bear potential ) , C-SSRS , documentation concomitant medication AEs , .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Metadoxine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>1 . Adolescent male female , 1317 year old , inclusive , screen visit , visible axillary hair . 2 . Diagnosed predominantly inattentive ADHD base DSM V criterion ADHD assess Adolescent ADHD Clinician Diagnostic Scale ( AdolCDS V1.2 ) . 3 . Clinical severity least moderate level ( Clinical Global ImpressionSeverity score 4 ) . 4 . STAI State score &lt; 52 , STAI Trait score &lt; 52 BDI score &lt; 19 . 5 . Sexually active subject childbearing potential must agree use effective contraceptive throughout study ( e.g. , oral contraceptive Norplant® ; reliable double barrier method birth control [ diaphragms contraceptive jelly ; cervical cap contraceptive jelly ; condom contraceptive foam ] ; intrauterine device ; vasectomy ; abstinence ) least month study , must negative serum pregnancy test Screening Visit . Females childbearing potential defined woman menarche 2 year postmenopause surgically sterilize . Males Female subject sexually active , agree abstinent throughout study , require use birth control . 6 . Subject able attend clinic regularly reliably . 7 . Subject able swallow tablet capsule . 8 . Able understand , read , write speak Hebrew fluently complete study related material . 9 . Parents legal authorized guardian ( LAR ) , subject , able understand sign write informed consent/assent participate study 10 . Subject parents/LARs provide assent/consent participate study . per applicable law regulation 11 . Subject weigh ≥40 kg ≤100 kg 1 . Subject psychiatric condition ( e.g. , schizophrenia personality disorder diagnose DSMV ) clinically significant unstable medical surgical condition may preclude safe complete study participation determine investigator use medical history , physical examination , neurological examination , laboratory test , electrocardiogram . Common diseases mild hypertension , wellcontrolled type 2 diabetes mellitus ( hemoglobin A1C &lt; 6.5 % ) , etc , allow per investigator 's judgment long stable control medical therapy constant least 8 week randomization subsequently throughout study . If concern suitability subject 's medical surgical condition , investigator review subject 's history medical monitor . 2 . Subject know suspected human immune deficiency virus positive status disease acquire immunodeficiency disorder , hepatitis C , hepatitis B , tuberculosis . 3 . Subject history allergy sensitivity Bcomplex vitamins . 4 . Subject history intellectual disability history suspicion autism spectrum disorder . 5 . Subject current clinically significant Axis I diagnosis ( ADHD ) accord KSADSPL lifetime history bipolar disorder psychosis . 6 . Subject use megadose vitamin B6/pyridoxine 28 day Randomization Visit . Subjects allow 28day washout megadose vitamin B6/pyridoxine Screening visit . Routine multivitamin supplement allow . 7 . Subject use highdose supplement omega3 fatty acid ≥ 500 mg least 1 day ( softgels , capsule , fish oil ; regular daily dietary consumption fish allow ) folic acid supplement ( routine multivitamin supplement ) 2 week Randomization Visit . 8 . Subject use investigational medication/treatment 30 day Screening Visit 9 . Subject used medication food supplement investigator medical monitor considers unacceptable 14day period randomization . This include , limited , sympathomimetic agent , clonidine , guanfacine , norepinephrine reuptake inhibitor , serotonin reuptake inhibitor , sedativehypnotics , benzodiazepine , sedate antihistamine , herbal preparation would confound safety efficacy assessment , narcotic . Questions regard acceptability medication food supplement ( melatonin ) discuss medical monitor study entry . 10 . Subject current drug alcohol dependence substance abuse disorder accord DSMV Text Revision criterion ( exclude nicotine ) history dependence within last 6 month . Subject also agree keep caffeine intake consistent refrain consume ≥300 mg per day caffeine ( three 8ounce serving coffee ) study . 11 . Subject suicidality , define active ideation , intent plan , significant lifetime suicidal behavior ( actual attempt , abort attempt , interrupt attempt , act preparation towards imminently make suicide attempt ) . Subjects exhibit history ( within previous 12 month ) nonsuicidal selfinjurious behavior exclude . 12 . Subject take prescription nonprescription ADHD medication 14 day randomization visit 28 day case atomoxetine.. 13 . Subject significantly visually impaired extent able correct prescription glass contact lenses 14 . Subject closely related sponsor , investigator , study staff . Eligibility subject relationship sponsor , investigator , study staff discuss medical monitor study entry . 15 . Subject condition , principal investigator 's opinion , would place subject risk influence conduct study interpretation result , include ( limited ) abnormally low intellectual capacity judge investigator . 16 . Subject fully comprehend implication protocol , comply requirement , incapable follow study schedule reason . 17 . Subject pregnant , lactating , use inadequate contraceptive method . 18 . Subject currently participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Inattention</keyword>
	<keyword>MDX</keyword>
</DOC>